Characteristics of intestinal flora of patients with hepatitis B related decompensated cirrhosis

doi:10.3877/cma.j.issn.1674-1358.2019.02.005

Abstract

Abstract:

Objective

To investigate the characteristics of intestinal flora of patients with ^{hepatitis B} related decompensated cirrhosis.

Methods

Total of 82 fecal specimens were collected from patients with hepatitis B related decompensated cirrhosis and healthy persons in Beijing Ditan Hospital, Capital Medical University, including 41 patients with ^{hepatitis B} related decompensated cirrhosis without other infection and 41 healthy controls. All samples were sequenced by 16S rDNA high-throughput sequencing. The composition, abundance and difference of bacterial flora were analyzed by Qiime, R and LEfSe softwares, while the difference of ecological imbalance ratio between the two groups was also analyzed.

Results

The abundance and diversity of fecal microflora of ^{hepatitis B} related decompensated cirrhosis group were significantly lower than that of healthy control group. The Beta diversity analysis of Weighted Unifrac showed that there was significant difference in intestinal microflora composition between the two groups (P = 0.004). On phylum level, the abundance of firmicutes was significantly decreased in ^{hepatitis B} related decompensated cirrhosis group (Z =-2.57, P = 0.045). On genus level, the abundance of Streptococcus, Fusobacterium, Veillonella, and Haemophilus were significantly increased in ^{hepatitis B} related decompensated cirrhosis group (all P < 0.05). While Lachnospira, Dorea, Dialister and Subdoligranulum were significantly decreased (all P < 0.05). LEfSe was used to compare the difference of flora and its function between the two groups. It was found that the biological indexes of Firmicutes Bacilli Lactobacillales, Clostridiales Lachnospira and Ruminococcaceae in both groups were significantly different (LDA > 4).

Conclusions

The diversity of intestinal flora and the relative abundance of thick-walled bacteria in patients with ^{hepatitis B} related decompensated cirrhosis without other infection were significantly decreased, and there was a significant imbalance of intestinal flora, but the degree of imbalance was mild and the number of bacteria with significant variation was less.

Key words: Hepatitis B, Decompensated cirrhosis, Gut microbiome

Yixuan Wang, Wei Li, Danying Cheng, Shun'ai Liu, Shan Zhang, Ming Han, Lin Zhu, Jing Sun, Huichun Xing. Characteristics of intestinal flora of patients with hepatitis B related decompensated cirrhosis[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2019, 13(02): 110-116.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2019.02.005

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2019/V13/I02/110

Figures/Tables 4

References 29

[1]	中华中华医学会肝病学分会，中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年更新版)[J]. 临床肝胆病杂志,2015,31(12):1941-1960.
[2]	Angeli P, Bernardi M, Villanueva C, et al. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol,2018,69(2):406-460.
[3]	宫嫚，周超，张宁, 等. 中西医结合治疗HBV相关慢加急性肝衰竭合并肝性脑病的效果分析[J]. 临床肝胆病杂志,2018,34(4):795-800.
[4]	Bouziat R, Jabri B. Breaching the gut-vascular barrier[J]. Science,2015,350(6262):742-753.
[5]	Brandl K, Kumar V, Eckmann L, et al. Gut-liver axis at the frontier of host-microbial interactions [J]. Liver Physiol,2017,312(1):413-419.
[6]	Segata N, Izard J, Waldron L, et al. Metagenomic biomarker discovery and explanation[J]. Genome Biology,2011,12(6):68-78.
[7]	Bajaj JS, Heuman DM, Hylemon PB, et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications[J]. J Hepatol,2014,60(5):940-947.
[8]	Anne-marie C, Dragos C. Microbiota, a key player in alcoholic liver disease[J]. Clin Mol Hepatol,2018,24(2):100-107.
[9]	Szabo G, Petrasek J. Gut-liver axis and sterile signals in the development of alcoholic liver disease[J]. Alcohol Alcoholism, 2017,52(4):414-424.
[10]	Bajaj JS, Acharya C, Fagan A, et al. Proton pump inhibitor initiation and withdrawal affects gut microbiota and readmission risk in cirrhosis[J]. AM J Gastroenterol,2018,113(8):1177-1186.
[11]	Acharya C, Bajaj JS. Altered microbiome in patients with cirrhosis and complications[J]. Clin Gastroenterol H,2019,17(2):307-321.
[12]	Chen Y, Yang F, Lu H et al. Characterization of fecal microbial communities in patients with liver cirrhosis[J]. Hepatology,2011,54(1):562-572.
[13]	Bian G, Gloor GB, Gong A, et al. The gut microbiota of healthy aged chinese is similar to that of the healthy young[J]. Msphere,2017,2(5):327-339.
[14]	Ren Z, Li A, Jiang J, et al. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma[J]. Gut,2018. [Published Online]
[15]	Qin N, Yang F, Li A, et al. Alterations of the human gut microbiome in liver cirrhosis[J]. Nature,2014,513(7516):59-64.
[16]	Bajaj JS, Hylemon PB, Ridlon JM, et al. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation[J]. AM J Physiol-Gastr L,2012,303(6):675-685.
[17]	Wei X, Yan X, Zou D, et al. Abnormal fecal microbiota community and functions in patients with hepatitis B liver cirrhosis as revealed by a metagenomic approach[J]. BMC Gastroenterol,2013,13(1):175-182.
[18]	J Mashima I, Nakazawa F. The influence of oral Veillonella species on biofilms formed by Streptococcus species[J]. Anaerobe,2014,28(1):54-61.
[19]	Thomas DY, Jarraud S, Lemercier B, et al. Staphylococcal enterotoxin-like toxins U2 and V, two new staphylococcal superantigens arising from recombination within the enterotoxin gene cluster[J]. Infect Immun,2006,74(8):4724-4734.
[20]	Kostic AD. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor immune microenvironment[J]. Cell Host Microbe,2013,14(2):207-215.
[21]	Byndloss MX, Olsan EE, Rivera-Chaveza F, et al. Microbiota-activated PPAR-gamma signaling inhibits dysbiotic Enterobacteriaceae expansion[J]. Science,2017,357(6351):570-575.
[22]	Kim CH. B cell-helping functions of gut microbial metabolites[J]. Microb Cell,2016,3(10):529-531.
[23]	Usami M, Miyoshi M, Yamashita H. Gut microbiota and host metabolism in liver cirrhosis[J]. World J Gastroenterol, 2015,21(1):11597-11608.
[24]	Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer[J]. Nat Rev Microbio,2014,12(10):661-672.
[25]	Savage JH, Lee-Sarwar KA, Sordillo J, et al. A prospective microbiome-wide association study of food sensitization and food allergy in early childhood[J]. Allergy,2017,73(1):145-152.
[26]	Muniz, Pedrogo DA, Jensen MD, et al. Gut microbial carbohydrate metabolism hinders weight loss in overweight adults undergoing lifestyle intervention with a volumetric diet[J]. Mayo Clin Proc,2018,93(8):1104-1110.
[27]	Wwhlstrom A, Sayin SI, Marschall HU, et al. Intestinal crosstalk between bile acids and microbiota and its Impact on host metabolism[J]. Cell Metab,2016,24(1):41-50.
[28]	Keitel V, Reinehr R, Gatsios P, et al. The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells[J]. Hepatology,2007,45(3):695-704.
[29]	Schaffler H, Herlemann DP, Klinitzke P, et al. Vitamin D administration leads to a shift of the intestinal bacterial composition in Crohn’s disease patients, but not in healthy controls[J]. J Digest Dis,2018,19(4):225-234.

组别	例数	年龄（± s，岁）	性别（男/女，例）	BMI （± s）	ALT [M（P25，P75），U/L）]	AST（U/L） [M（P25，P75），U/L）]
健康对照组	41	32 ± 6	15/26	21.5 ± 1.6	12（10.8，26.5）	19（16.2，21.3）
乙型肝炎失代偿期肝硬化组	41	42 ± 9	23/18	22.2 ± 1.1	23（18.7，36.7）	33（22.1，49.2）
统计量	?	t = 8.49	χ² = 3.13	t = 1.06	Z = 3.29	Z = 5.43
P值	?	0.038	0.080	0.060	0.001	< 0.001
组别	例数	ALB [M（P25，P75），g/L]	总胆红素[M（P25，P75），μmol/L]	INR [M（P25，P75）]	MELD评分[M（P25，P75），分]
健康对照组	41	47（45.4，49.6）	12（8.8，15.8）	—	—
乙型肝炎失代偿期肝硬化组	41	36（31.2，40.7）	22（13.5，31.6）	1.2（1.1，1.4）	7.8 ± 4.9
统计量	?	Z =－6.80	Z = 4.26	—	—
P值	?	< 0.001	< 0.001	—	—

组别	例数	年龄（± s，岁）	性别（男/女，例）	BMI （± s）	ALT [M（P25，P75），U/L）]	AST（U/L） [M（P25，P75），U/L）]
健康对照组	41	32 ± 6	15/26	21.5 ± 1.6	12（10.8，26.5）	19（16.2，21.3）
乙型肝炎失代偿期肝硬化组	41	42 ± 9	23/18	22.2 ± 1.1	23（18.7，36.7）	33（22.1，49.2）
统计量	?	t = 8.49	χ² = 3.13	t = 1.06	Z = 3.29	Z = 5.43
P值	?	0.038	0.080	0.060	0.001	< 0.001
组别	例数	ALB [M（P25，P75），g/L]	总胆红素[M（P25，P75），μmol/L]	INR [M（P25，P75）]	MELD评分[M（P25，P75），分]
健康对照组	41	47（45.4，49.6）	12（8.8，15.8）	—	—
乙型肝炎失代偿期肝硬化组	41	36（31.2，40.7）	22（13.5，31.6）	1.2（1.1，1.4）	7.8 ± 4.9
统计量	?	Z =－6.80	Z = 4.26	—	—
P值	?	< 0.001	< 0.001	—	—

Please choose a citation manager

Content to export